1

| 1 | The Development of the Substance Use Disorder Screening Test (SUDST) |
|----|--|
| 2 | according to the DSM-5 |
| 3 | |
| 4 | Running title: The Substance Use Disorder Screening Test |
| 5 | |
| 6 | Sukuma Saengduenchai, Ph.D. ¹ , Sumnao Nilaban, Ph.D. ¹ , Tanya Singtho, |
| 7 | M.Sc. ¹ , Apichart Ranuwattananon, M.D. ¹ , Rasmon Kalayasiri, M.D. ^{2, 3,} * |
| 8 | |
| 9 | ¹ Princess Mother National Institute on Drug Abuse Treatment, Department of |
| 10 | Medical Services, Ministry of Public Health, Pathumthani, Thailand |
| 11 | ² Department of Psychiatry, Faculty of Medicine, Chulalongkorn University, |
| 12 | Bangkok, Thailand |
| 13 | ³ Department of Psychiatry, King Chulalongkorn Memorial Hospital, Bangkok, |
| 14 | Thailand |
| 15 | * Correspondence address: Rasmon Kalayasiri, Department of Psychiatry, |
| 16 | Faculty of Medicine, Chulalongkorn University, 1873 Rama 4 Road, Pathumwan, |
| 17 | Bangkok 10330, Thailand. Telephone number +66 2256 4000 Ext. 61559. Email |
| 18 | address : rasmon.k@chula.ac.th |
| 19 | |

NOTE: This preprint reports new research that has not been certified by peer review and should not be used to guide clinical practice.

2

20 Abstract

Objectives: A screening tool for substance use disorders is most needed for
patient care and referral. The study aims to develop the Substance Use Disorder
Screening Test (SUDST) to classify the severity of substance use disorders
based on the Fifth Edition of the Diagnostic and Statistical Manual of Mental
Disorders (DSM-5).

26 **Methods:** Eleven items of the SUDST, developed based on the DSM-5, were

tested on 207 participants who were receiving treatment for methamphetamine

use. Participants were interviewed with the SUDST, the screening test of the

29 Ministry of Public Health Version 2 (V.2), the Mini International Neuropsychiatric

30 Inventory (M.I.N.I) and were clinically diagnosed by attending psychiatrists.

31 **Results:** Cronbach's alpha coefficient was 0.79. The SUDST was highly

32 significantly associated with the M.I.N.I., V.2, and the clinical diagnosis (p <

0.001). Factor analysis showed three components: 1) preoccupation and loss of

control 2) risky/harmful use and 3) impact to bio-psychosocial aspects. Of the

total score of 11, the cut-off points to identify severe, moderate, and mild levels of

risk were \geq 7, 5-6, and 3-4, respectively with sensitivity = 72.7%-96.5% and

37 specificity = 61.9%-88.7%.

Conclusions: The SUDST had high reliability and validity that could be used for
 screening risk for substance use disorders.

40

41 **Key words:** Addiction, diagnosis, DSM, psychostimulants, scale development

42

44 Introduction

45

Substance use has caused problems in all continents around the world, affecting 46 individuals, families, communities, and societies. In the South East Asian countries, 47 illicit substance 48 the most common use was cannabis, kratom, and methamphetamine (1-3), which the latter (commonly known as speed pill (yaba) 49 50 and crystal meth (ice)) caused the most problem in the region. The Princess Mother National Institute for Drug Abuse Treatment (PMNIDAT), the first and largest 51 52 treatment center for substance use disorders in Central Thailand and in the South East Asia with 600 in-patient bed capacities, reported statistics which showed 53 nearly half of the patients having methamphetamine use disorder (4), which has 54 been increasing each year from 40.26% in 2016, increasing to 46.39% in 2017, 55 and to 54.35% in 2018. Most of the inpatients with methamphetamine use disorder 56 in this treatment center had a history of psychiatric symptoms including anxiety or 57 suspiciousness (91.2%), depression (86.8%), and hallucination (85.7%) (5). 58

59

An effective and user-friendly assessment tool for substance use disorders is most 60 needed for patient care and referral to the allocated treatment settings for patient 61 management. Treatment facilities for substance use disorder in Thailand has used 62 The Ministry of Public Health's Screening Test Version 2 (V.2), which was adapted 63 from the World Health Organization (WHO)'s Alcohol, Smoking, and Substance 64 Involvement Screening Test (ASSIST) (6, 7). The V.2 has been used to assess 65 levels of risk of substance use for allocating persons who used substance to each 66 level of the formal treatment settings in Thailand. Persons who had low risk from 67 the screening test were usually referred to the outpatient treatment at the general, 68

4

provincial, or district hospitals with service for persons who used substances while 69 those with moderate risk were usually sent to the treatment program at the 70 designated government locations in each province that was operated in 71 collaboration between the Ministry of Public Health, Ministry of Defense, and 72 Ministry of Justice, and Ministry of Interior (8). For people with high risk of 73 methamphetamine use disorder as screened by the V.2 were usually sent to the 74 75 inpatient treatment at the substance treatment facilities widely spread over four parts of Thailand. 76

77

In 2013, the American Psychiatric Association issued the Fifth Edition of the 78 Diagnostic and Statistical Manual for Mental Disorder (DSM-5) (9) that view the 79 substance use problems as a continuum of disorder from mild, moderate to severe 80 substance use disorder. As such, the DSM-5 diagnosis for substance use 81 disorders, especially methamphetamine, the most problematic illegal substance in 82 the region, has never been tested or compared to the Thai V.2. In the study, we 83 compared the DSM-5 criteria for substance use disorders with the current formal 84 use of V.2, which is the main screening tool for allocating persons with illegal 85 problems in Thailand to receive treatment by using the Substance Use Disorder 86 Screening Test (SUDST), that had been newly developed based on the DSM-5 87 criteria symptoms. The SUDST was then tested in the study for validity and 88 reliability with clinical diagnosis by clinicians and the Mini International 89 Neuropsychiatric Interview (M.I.N.I.). The study aims to investigate the reliability 90 and validity of this new screening tool for clinical substance use disorder based on 91 DSM-5 criteria. The new instrument may be used accordingly with other personal 92

5

and societal factors for allocating persons who use substance to get appropriate
treatment for substance use based on their needs.

95

96 Methods

97

Two-hundreds and seven male and female patients aged 13 years and over 98 99 receiving outpatient service for methamphetamine use from the PMNIDAT and its satellite hospitals in the four regions of Thailand including Central (PMNIDAT 100 101 or Thanyarak Pathumthani), North (Thanyarak Chiang Mai), Northeast (Thanyarak Khon Kaen), and South (Thanyarak Songkla) were interviewed 102 between August 2017 to December 2018 by attending psychiatrists for DSM-5 103 104 substance use disorder diagnosis. All of them had at least 3 years experience in addiction treatment. The attending psychiatrists were blinded to the diagnosis 105 made by the questionnaires used in the study. Risk and methamphetamine use 106 disorder were obtained using the SUDST, the M.I.N.I. for methamphetamine use 107 disorder and the V.2 by research nurses (with at least 5 years experience in 108 addiction treatment). All interviewers attended a training class for M.I.N.I., 109 SUDST, and V.2. Individuals with cognitive impairment or psychosis (e.g., 110 history of being diagnosed with dementia, psychotic disorder) were excluded 111 112 from the study. The study has been approved by the Ethics Committee of the PMNIDAT with study number: 59023. 113

114

The SUDST were developed from the DSM-5 criteria for substance use
disorders (9). The test had 11 items for the respondent to answer yes or no to

each question that correspond to what participants have experienced in the past

6

12 months of their substance use. The test was examined for content validity 118 from 5 experts in the fields of addiction, behavioral science, and psychometric 119 120 test. The Index of Item-Objective Congruence is 0.65. The screening tool was then adjusted per suggestion and tested in 30 subjects (10) with substance use. 121 The language was then further adjusted based on suggestion from this initial field 122 testing. The language-adjusted screening test was then tested for inter-rater 123 124 reliability by two independent interviewers with the time interval not more than 1 week apart. The content of the screening test includes four aspects of addiction 125 126 including impaired control of substance use, social impairment from substance use, risky use of substance, and the pharmacological aspect of addiction. 127 128 The V.2 is the screening tool for referral persons with substance use problems in

129 130 Thailand. It was developed by the Ministry of Public Health (MOPH) and was known as "Screening Form – MOPH: Version 2" or V.2 in brief. The test was 131 adapted from the World Health Organization (WHO)'s Alcohol, Smoking, and 132 Substance Involvement Screening Test (ASSIST), comprising of 6 questions 133 related to behaviors of substance use, the impact of substance use, and the 134 135 concern from others about one's substance use in the past 3 months. Each item has 5 answer options from never, only 1-2 times total, about 1-3 times per month, 136 about 1-4 days per week, and 5-7 days per week (almost every day) The total 137 score was categorized to three levels (e.g., mild, moderate, and severe) risk for 138 substance dependence. 139

140

The M.I.N.I., Methamphetamine Section, Thai version was adapted for the
diagnosis of DSM-5 Substance Use Disorder in the study by R.K. and colleagues.

7

| 143 | The original Thai M.I.N.I had two parts for substance diagnoses based on DSM- |
|-----|--|
| 144 | IV criteria to diagnose methamphetamine dependence (7 items) and |
| 145 | methamphetamine abuse (4 items). In the current study, the item related to legal |
| 146 | problem from substance use was excluded from algorithm of diagnosis and |
| 147 | replaced by an item related to craving for substance in order to correspond to the |
| 148 | DSM-5 criteria for substance use disorder. Having 2-3, 4-5, and 6 or more criteria |
| 149 | mean having mild, moderate, or severe level of substance use disorders. |
| | |

150

151 Data from all questionnaires were checked for completeness by a researcher.

152 The total duration of data collection was 16 months. First we tested for reliability

of the SUDST by using Cronbach's alpha coefficient for internal consistency.

154 Concurrent validity of the questionnaire for DSM-5 diagnosis for substance use

disorder was tested by using contingency coefficient with the clinical diagnosis. In

addition, construct validity was tested by using Factor analysis. Finally, the

157 SUDST was tested to determine the cut off point for the risk of having substance

use disorder as provided by clinicians' judgment. Cut off points for differentiating

levels of substance use disorders were analyzed by using area under the

receiver operating characteristic (ROC) curve to have sensitivity and specificity

values of the SUDST, the new screening tool for clinical substance use disorder
 based on DSM-5 criteria.

163

164 **Results**

165 Table 1 shows demographics of the participants in the study. Of 207 participants,

most were male (88.4%), single (60.9%), and graduated from high school

8

| 167 | (57.0%). | The mean age was | s 29 years (SD | = 8.3, Min = 14 | , Max = 53). Twenty- |
|-----|----------|------------------|----------------|-----------------|----------------------|
|-----|----------|------------------|----------------|-----------------|----------------------|

seven percent of the participants were unemployed and 67.1% had drug related 168

offences in the past. Table 2 shows the substance use data. Most of the 169

- 170 participants used methamphetamine and other illegal substances including
- cannabis and kratom (67.6%). About one-third (29.0%) used speed pills (yaba) 171
- only without any other illegal substance. The average daily amount of speed pills 172
- (yaba) consumed was 4 pills and the average duration of substance use was 7 173
- years. Most individuals who used crystal meth (ice) did not know the daily amount 174

175 in grams.

| 177 | Table 1. Demographic data of the participants in the study (N = 207). | |
|-----|---|--|
| | | |

| | n (N = 207) | % |
|-----------------------------|----------------------|-------------------|
| Gender | | |
| Male | 183 | 88.4 |
| Female | 24 | 11.6 |
| Marital status | | |
| Single | 126 | 60.9 |
| Married | 65 | 31.4 |
| Divorced, widow, separated | 13 | 6.3 |
| Do not answer | 3 | 1.4 |
| Age (years) | mean = 29 SD = 8.3 M | lin = 14 Max = 53 |
| ≤19 | 27 | 13.0 |
| 20-29 | 89 | 43.0 |
| 30-39 | 66 | 31.9 |
| 40-49 | 21 | 10.2 |
| ≥50 | 4 | 1.9 |
| Level of education | | |
| None | 1 | 0.5 |
| Primary school | 45 | 21.8 |
| High school | 118 | 57.0 |
| Vocational school | 28 | 13.5 |
| Bachelor or graduate degree | 15 | 7.2 |
| Occupation | | |
| Unemployed | 56 | 27.0 |
| Students | 11 | 5.3 |
| Employees | 73 | 35.5 |
| Farming / Fishery | 16 | 7.6 |
| Business owners | 39 | 18.8 |
| Government officers | 10 | 4.8 |
| Do not answer | 2 | 1.0 |
| Relationship in the family | | |
| Good | 117 | 56.5 |
| No interaction / distant | 21 | 10.1 |
| Fight some times | 63 | 30.5 |
| Fight almost always | 6 | 2.9 |
| Drug offence (s) | | |
| Ever | 139 | 67.1 |
| Never | 68 | 32.9 |
| | | |

9

179 **Table 2.** Substance and methamphetamine use data in the participants of the

180 study.

| | n (N = 207) | % |
|-----------------------------------|------------------------------------|------|
| Substance use | | |
| Speed pills (yaba) only | 60 | 29.0 |
| Crystal meth (ice) only | 3 | 1.5 |
| Speed pills and crystal meth only | 4 | 1.9 |
| Yaba/ice and other substances | 140 | 67.6 |
| Daily amount of yaba use (pills) | mean =4 SD = 5.1 Min =0.5 Max 48 | |
| ≤5 | 143 | 72.9 |
| 6-10 | 20 | 10.1 |
| 11-15 | 4 | 2.0 |
| 15 and above | 2 | 1.0 |
| Did not answer | 29 | 14.0 |
| Duration of yaba use (years) | mean =84 SD = 74.4 Min =12 Max 576 | |
| ≤5 | 104 | 52.5 |
| 6-10 | 45 | 22.7 |
| 11-15 | 25 | 12.6 |
| 16-20 | 15 | 7.6 |
| 20 or more | 4 | 2.0 |
| Did not answer | 5 | 2.6 |
| Daily amount of ice use (grams) | | |
| < 1 gram | 17 | 25.4 |
| 1 gram and more | 4 | 5.9 |
| Did not answer | 46 | 68.7 |
| Duration of ice use (years) | mean =36 SD = 49.9 Min =2 Max 240 | |
| ≤1 | 10 | 14.9 |
| 2-5 | 10 | 14.9 |
| 6 or more | 2 | 2.9 |
| Did not answer | 45 | 67.3 |

181

Regarding reliability of the SUDST, Cronbach's alpha coefficient is 0.79 which 182 reflects good internal consistency of the instrument but Cohen's kappa is only 183 0.45 for inter-rater reliability. Construct validity was tested by using Factor 184 analysis of the 11 questions used in the questionnaire and shown in Table 3. 185 186 Extraction method was used with the Principal component analysis by the Varimax rotation. Three factors were found including preoccupation / loss of 187 control of use comprising of 4 questions, Risky or harmful use comprising of 3 188 questions, and the impact of use comprising of 4 questions. The correlation 189 between each construct is in high level (more than 0.4). The factor loading could 190 describe the variance at 51.8%. Specifically, Factor 1 could describe the variance 191 at 32.3%, Factor 2 could describe at 10.1%, and Factor 3 could describe at 9.3%. 192 Concurrent validity of the SUDST for Substance Use Disorder with other 193

10

- measures including clinical diagnosis by physicians and the M.I.N.I., and the V.2
- were high by using contingency coefficient (p < 0.001) (Table 4).
- 196
- 197 **Table 3.** Factor loading of the 11 items of the Substance Use Disorder Screening
- 198 Test (SUDST).

| Factors | ltem | | Factor loading |
|--------------------|------|--|-------------------|
| Factor 1 | 1 | Used more than intention | 0.72 |
| Preoccupation / | 3 | Spent a lot of time for substance | 0.67 |
| loss of control of | 2 | Wanted to stop or cut down but unsuccessful | 0.55 |
| substance use | 4 | Craving for substance | 0.49 |
| Factor 2 | 9 | Used despite the substance caused problems | 0.73 |
| Risky / | 8 | Used in risky situations | 0.69 |
| harmful use | 10 | Tolerance | 0.54 |
| Factor 3 | 11 | Withdrawal symptoms | 0.72 |
| Impact of use | 6 | Used despite having problems with others | 0.69 |
| | 7 | Decreased healthy recreational activities | 0.66 |
| | 5 | Used until impairment in work, school, or family | 0.41 |

199

- 200 Table 4. Concurrent validity of the Substance Use Disorder Screening Test
- 201 (SUDST) with the M.I.N.I., V.2, and clinical diagnosis.

| Measures | Coefficient | P-values |
|---|-------------|----------|
| Mini international neuropsychiatric Inventory (M.I.N.I) | .51 | <.001 |
| V.2 | .57 | <.001 |
| Clinical/physician diagnosis based on DSM-5 | .54 | <.001 |

203

Table 5 shows cut off points of the SUDST to determine level substance use

205 disorder and categorize them into three groups based on clinical judgment

- including low, moderate, and high risk of substance use disorder according to the
- 207 physician's judgement. The score at 7 or higher had high sensitivity (77.9%) and
- specificity (72.7%) to determine the high risk group. The scores at 5 or 6 can
- define the moderate risk group (sensitivity = 88.7%; specificity = 61.9%) and the

11

scores at 3 or 4 can define the low risk group (sensitivity = 96.5%, and specificity

= 66.7%). The Area Under the Curve (AUC) is in good ranges (0.83 - 0.87).

212

| 213 | Table 5. Cut – off point for the Substance Use Disorder Screening Test (SUDST) |
|-----|--|
| 214 | comparing to the clinical judgment based on DSM-5 criteria for substance use |
| | |

disorders.

| Level of substance use disorder | Cut-off point | Sensitivity | Specificity | Area under curve (95% CI) |
|------------------------------------|---------------|-------------|-------------|------------------------------|
| Severe | ≥7 | 77.9 | 72.7% | 0.83 (0.76-0.90) |
| Moderate | 5-6 | 88.7% | 61.9% | 0.87 (0.81-0.93 |
| Mild | 3-4 | 96.5% | 66.7% | 0.85 (0.69-1.0) |

216

217 Discussion

The SUDST is a screening test based on DSM-5 symptom criteria for substance 218 219 use disorders comprising of 11 questions regarding to the past 12 months experience of substance use with yes or no answers. The score ranging from 0 to 220 11. It is suitable for addiction researchers/specialists to evaluate people who use 221 substance regarding to DSM-5 diagnosis of substance use disorder by using 222 DSM-5 diagnostic criteria or to evaluate risk of substance use especially 223 methamphetamine by using the new cut off point for clinical purposes such as 224 allocation of persons to specific settings (i.e. outpatient, inpatient, long-termed 225 rehabilitation) (8). 226

227

The reliability by internal consistency of the Thai SUDST instrument is in good level with Cronbach's alpha coefficient = 0.79. Construct validity by Principal component analysis found 3 factors covered 51.8% of the variance including

12

| 231 | 32.3%, 10.1% and 9.3%, for Factor 1 (preoccupation / loss of control), Factor 2 |
|-----|--|
| 232 | (risky and harmful use), and Factor 3 (impact of use), respectively. Concurrent |
| 233 | validity of the instrument is good when compared with three measures including |
| 234 | M.I.N.I., V.2, and clinical diagnosis/judgment (P < 0.001). In addition to using the |
| 235 | DSM-5 diagnostic criteria for substance use disorders, new scores of the |
| 236 | instrument could make cut off points able to divide subjects into three categories |
| 237 | comparable to the clinical judgment including high risk (score = 7 or more with |
| 238 | sensitivity = 77.9% and specificity = 72.7%), moderate risk (score = 5 - 6 with |
| 239 | sensitivity = 88.7% and specificity = 61.9%), and low risk (score = 3 - 4 with |
| 240 | sensitivity = 96.5% and specificity = 66.7%) with the AUC in good levels (0.83 - |
| 241 | 0.87). |

242

In the study, all of the participants used methamphetamine in the past 12 months 243 and 67% of them used it with other illegal substances. This proportion is 244 245 consistent with the annual information that more than 50% of the patients with methamphetamine use disorders at the treatment centre used other illegal 246 substances in the past 12 months (4). Using more than one substance increase 247 harm and negative outcomes which might interfere with level of risk and result to 248 different result of the screening (11). We did not exclude participants who used 249 more than one substances in this study. However, including persons who used 250 other substances than methamphetamine reflects the real world situation that 251 would make the SUDST to be used generally. 252

13

Factor analysis of the SUDST revealed three components including 254 preoccupation or loss of control, risky/harmful use, and impact of use. The result 255 is consistent with other instruments related to measuring the severity or risk of 256 substance. For example, Khon Kaen University-Volatile Use Disorder 257 Identification Test (KKU-VOUDIT) (12), a ten-question questionnaire, comprised 258 of three components including intoxication or impact of use, preoccupation or loss 259 260 of control, and harmful use. Nevertheless, The DSM-5 diagnostic criteria for substance use disorder suggested four components of the disorder including 261 262 impaired control, social impairment, risky use, and pharmacological component (9). In general, preoccupation or loss of control over substance use is usually 263 considered to be the core symptoms of addiction by the definition of addiction 264 that continuing to use or seek for substances despite knowing that it causes harm 265 to oneself. Four items were in this core component to reflect the impaired control 266 including 1) using substance more than intended 2) unable to stop or cut down 267 substance use 3) spending a lot of time using/interacting with the substance and 268 4) craving for substance. 269

270

The pharmacological aspect has not appeared as a component in the study. 271 Specifically, the two questions reflecting the pharmacological aspect of substance 272 use disorder (e.g., tolerance and withdrawal) were each either included into the 273 component of risky / harmful use or in component of the impact of use. Regarding 274 the items for the component of risky/harmful use, they include 1) using substance 275 in a risky situation (i.e., driving, operating machinery) 2) using substance despite 276 knowing it causes physical, psychological, or other problems and 3) increasing 277 278 the amount of substance to get the same effect or experiencing reduced effect

14

while using the same amount of substance. It is understandable that tolerance of
a substance especially the question asking about increasing the amount of
substance in order to get the same effect may be viewed as risky/harmful use by
the persons who use substance.

283

Likewise, having withdrawal symptoms from methamphetamine, including fatigue, hypersomnia, irritable or depressed mood may be viewed as negative impacts of substance use and are included in the component of impacts of use. The other items in this component include 1) regular use of substance until having impaired function for work, study, or family 2) using substance despite it caused interpersonal relationship (i.e., domestic violence, physical or verbal fights) and 3) reduced social or recreational activities due to substance use.

291

Several limitations of the study deserve to be mentioned. The study took place in 292 addiction treatment settings so the most of the participants mostly had problems 293 from substance use and might not reflect those with milder level of substance 294 use. Further study should test the instrument in primary health care where more 295 persons with mild level or use without any level of substance use disorder would 296 be included. In addition, larger sample size would give more power to test the 297 instrument. People who use other substances including illegal substances (i.e., 298 299 cannabis, kratom, opioids) or legal substances (i.e., alcohol, tobacco) should be recruited to test the reliability and validity of the instrument. 300

15

By using the SUDST, as well as the risk assessment by the V.2 which has 302 already been formally used, the severity of the disorder is divided into three levels 303 of risk including mild, moderate, and severe. By doing so, substance use disorder 304 is viewed as a spectrum and not a binary of disease (e.g., abuse or dependence). 305 This work is in agreement with the ASSIST (7) and the DSM-5 diagnostic criteria 306 (9) (which is the basis of the SUDST). The SUDST cut-off point for the mild level 307 308 of the risk for substance use disorder has 97% sensitivity, making the instrument a good candidate for screening persons with risky behavior of substance use to 309 310 the various level of severity and referral to an appropriate setting at the beginning stages of the diseases. Therefore, the SUDST is an option to be used in health 311 care setting to differentiate the severity of substance use. 312

313 Acknowledgements

- We would like to thank Viroj Verachai, M.D. for facilitating the process of the
- study. We would also like to thank all participants for their time and efforts. R.K.'s
- research career is supported by the Centre for Addiction Studies (supported by
- The Thai Health Promotion Foundation) and the R01 DA037974 and the D43
- 318 TW009087/TW/FIC NIH HHS, US.

319 Conflicts of interest statement:

320 The authors report no conflicts of interest.

321 **References**

- 1. UNODC. World Drug Report 2021. United Nations publication; 2021.
- 323 Report No.: Sales No. E.21.XI.8.

16

2. Centre for Addiction Studies. Survey on substance uses and attitude

toward substances in the Thai population aged 15-65 years. Faculty of Medicine,

326 Chulalongkorn University, Bangkok; 2020.

- 327 3. Kanato M, Leyatikul P, Wonguppa R. Size estimation of substances users 328 population in Thailand 2019. ONCB journal. 2020;36(2):37-48.
- 4. Princess Mother National Institute on Drug Abuse Treatment. Statistics on

330 substance abuse treatment at the Princess Mother National Institute on Drug

Abuse Treatment in 2015-2019. Pathumtani; 2019.

332 5. Rukngan W, Singhtho T, Noikorn S, Phonsamrong S, Nuannum D,

333 Phajaroen S. Psychiatric symptoms in Amphetamine-Type stimulants (ATS) in-

patients at Thanyarak Institute. Thai Journal of Addiction. 2013;1:6-14.

335 6. Integrated Management of Alcohol Intervention program. The Alcohol,

336 Smoking and Substance Involvement Screening Test (ASSIST) Manual for use in

337 primary care, Thai version. Integrated Management of Alcohol Intervention

338 program; 2011.

World Health Organization. The Alcohol, Smoking and Substance
Involvement Screening Test (ASSIST) : Manual for use in primary care. World
Health Organization; 2010.

Narcotics Control Management Center Thailand Ministry of Public Health.
 Strategic plan for substance abuse treatment and rehabilitation budget years
 2021-2023. 2021.

American Psychiatric Association. Diagnostic and Statistical Manual of
 Mental Disorders, Fifth Edition (DSM-5). Arlington, VA: American Psychiatric
 Publishing; 2013.

10. Kongsomboon K. Textbook of edidemiological research for medical

349 students. Bangkok2014.

- 11. Australian Government Department of Health. Patterns of use and harms
- 351 associated with specific populations of methamphetamine users in Australia -
- 352 exploratory research. <u>https://www1.health.gov.au/;</u> 2008.
- 12. Arunpongpaisal S, Kanato M, Chiaviriyabunya I, Daosodsai S, Kamproa S.
- 354 Tools development and validity testing of Khon Kaen University-Volatile Use
- 355 Disorder Indentification Test (KKU-VOUDIT) to classify severity of volatile users.
- ³⁵⁶ J Psychiatr Assoc Thailand. 2010;55(1):63-78.